TITLE

Anti-VEGF aids PRP in diabetic retinopathy

PUB. DATE
April 2008
SOURCE
Ocular Surgery News Europe/Asia-Pacific Edition;Apr2008, Vol. 19 Issue 4, p1
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article provides information on anti-vascular endothelial growth factor (VEGF) and its ability to aid panretinal photocoagulation (PRP) in treating severe proliferative diabetic retinopathy. A combination of bevacizumab or Avastin and PRP was found to be more effective in the regression of the new vessels and resolution of macular edema in patients with diabetic retinopathy. An overview of a prospective study by Murat Oncel on bevacizumab's efficacy is offered.
ACCESSION #
31655510

 

Related Articles

  • Advances in the management of diabetic macular oedema based on evidence from the Diabetic Retinopathy Clinical Research Network. Lik Thai Lim; Seen Nee Chia; Gupta, Manish; Ah-kee, Elliott Yann; Chew, Nejia // Singapore Medical Journal;May2015, Vol. 56 Issue 5, p237 

    The Diabetic Retinopathy Clinical Research Network (DRCR.net) performs studies on new treatments for diabetic retinopathy. This review aims to summarise recent findings from DRCR.net studies on the treatment of diabetic macular oedema. We performed a PubMed search of articles from the DRCR.net,...

  • Intravitreal bevacizumab injection alone or combined with macular photocoagulation compared to macular photocoagulation as primary treatment of diabetic macular edema. Jovanović, Sandra; Čanadanović, Vladimir; Sabo, Ana; Grgić, Zorka; Mitrović, Milena; Rakić, Dušan // Vojnosanitetski Pregled: Military Medical & Pharmaceutical Journ;Oct2015, Vol. 72 Issue 10, p876 

    Background/Aim. Within diabetic retinopathy (DR), diabetic macular edema (DME) is one of the leading causes of the loss of visual acuity. The aim of this study was to determine the efficacy of the intravitreal vascular endothelial growth factor (VEGF) inhibitor application alone or combined with...

  • Effect of Intravitreal Bevacizumab on Vascular Endothelial Growth Factor Expression in Patients with Proliferative Diabetic Retinopathy.  // Yonsei Medical Journal;1/1/2011, Vol. 52 Issue 1, p151 

    No abstract available.

  • Anti-VEGF injection improves PRP results in diabetic retinopathy. Loughery, Jessica // Ocular Surgery News Europe/Asia-Pacific Edition;Apr2008, Vol. 19 Issue 4, p30 

    The article provides information on the impact of anti-vascular endothelial growth factor (VEGF) injection on panretinal photocoagulation (PRP) results in diabetic retinopathy. A study by Murat Oncel, found that administering intravitreal bevacizumab or anti-VEGF before PRP is more effective in...

  • Laser photocoagulation remains option for diabetic macular edema. Bechtel, Bryan // Ocular Surgery News;8/10/2010, Vol. 28 Issue 15, p20 

    The article discusses laser photocoagulation as a viable option in the treatment of diabetic macular edema. The insufficiency of information on response to therapy in some patients has driven a search for alternative treatments that can deliver higher success rates, such as intravitreal...

  • A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Nicholson, Benjamin P.; Schachat, Andrew P. // Graefe's Archive of Clinical & Experimental Ophthalmology;Jul2010, Vol. 248 Issue 7, p915 

    Diabetic retinopathy (DR) is a leading cause of vision loss in the working-age population worldwide. Many observational and preclinical studies have implicated vascular endothelial growth factor (VEGF) in the pathogenesis of DR, and recent successes with anti-VEGF therapy for age-related macular...

  • Diabetic Papillopathy: Current and New Treatment Options. Giuliari, Gian P.; Sadaka, Ama; Chang, Peter Y.; Cortez, Rafael T. // Current Diabetes Reviews;May2011, Vol. 7 Issue 3, p171 

    Diabetes mellitus is a growing global epidemic. Patients with this disease present with a variety of health conditions, including a number of ocular complications that threaten vision, such as proliferative diabetic retinopathy and macular edema. Diabetic papillopathy, another potential ocular...

  • The Angio-Fibrotic Switch of VEGF and CTGF in Proliferative Diabetic Retinopathy. Kuiper, Esther J.; Van Nieuwenhoven, Frans A.; de Smet, Marc D.; van Meurs, Jan C.; Tanck, Michael W.; Oliver, Noelynn; Klaassen, Ingeborg; Van Noorden, Cornelis J. F.; Goldschmeding, Roel; Schlingemann, Reinier O. // PLoS ONE;2008, Vol. 3 Issue 7, p1 

    Background: In proliferative diabetic retinopathy (PDR), vascular endothelial growth factor (VEGF) and connective tissue growth factor (CTGF) cause blindness by neovascularization and subsequent fibrosis, but their relative contribution to both processes is unknown. We hypothesize that the...

  • Intravitreal Anti-VEGF Drugs as Adjuvant Therapy in Diabetic Retinopathy Surgery. Montero, Javier A.; Ruiz-Moreno, José Ma; Correa, Maria E. // Current Diabetes Reviews;May2011, Vol. 7 Issue 3, p176 

    The use of intravitreal anti vascular endothelial growth factor (anti-VEGF) drugs such as pegaptanib, ranibizumab and bevacizumab has been widely reported to treat complications such as macular edema and rubeosis. During the past few years they have also been used as an adjuvant therapy to...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics